1-3 of 3
Michael P. Carroll, MD
Close
Sort by
Journal Articles

Pentostatin and Alemtuzumab: An Immunosuppressive Nonmyeloablative Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).

Faiz Anwer, MD, Michael P. Carroll, MD, Myke R. Green, PharmD, Lee Cranmer, MD, PhD, Leona Downey, MD, Linda Garland, MD, Katayoun Moini, MHS, PA-C, Daniel O. Persky, MD, Rachel Swart, MD, PhD, Andrew M. Yeager, MD
Journal: Blood
Blood (2009) 114 (22): 4312.
https://doi.org/10.1182/blood.V114.22.4312.4312
Published: 2009
Journal Articles

Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.

Paul G. Richardson, MD, Asher A. Chanan-Khan, MD, Sagar Lonial, MD, Amrita Y. Krishnan, MD, Michael P. Carroll, MD, Maher Albitar, MD, Justin Kopit, PhD, David Berman, MD, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 2890.
https://doi.org/10.1182/blood.V114.22.2890.2890
Published: 2009
Journal Articles

Bortezomib Induces Rapid Upregulation of Topoisomerase IIα and Demonstrates Schedule-Dependent Synergistic Cytotoxicity with Anthracyclines and Etoposide in Acute Myeloid Leukemia and Myeloma Cell Lines.

Michael P. Carroll, MD, Olin Feuerbacher, Andrew M. Yeager, MD, Terry H. Landowski, PhD
Journal: Blood
Blood (2005) 106 (11): 2478.
https://doi.org/10.1182/blood.V106.11.2478.2478
Published: 2005